Showing posts with label medical device. Show all posts
Showing posts with label medical device. Show all posts

Sunday, February 7, 2016

Israeli company Regentis Biomaterials Raises $15M, round led by Chinese group Haisco

Israeli biomedical company Regentis Biomaterials announced today the closing their $15 million Series D funding round, led by Chinese pharmaceutical group Xizang Haisco Pharmaceutical Group Co. Ltd, a leading Chinese pharmaceutical group listed on the Shenzhen Stock Exchange (SHE:002653).

Also participated in the round existing investors: Medica Venture Partners, SCP Vitalife Partners, Italian asset manager Generali Investment, and the technology transfer company of the Technion, T3.

Regentis CEO and President is Dr. Alastair Clemow.

Regentis Biomaterials is developing hydrogels for tissue regeneration originally developed at the Technion University by Dr. Dror Seliktar. The company’s flagship product, GelrinC™, combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance. Currently the treatment is under clinical trials for the treatment of articular cartilage lesions.

Haisco Pharmaceutical Group, founded in 2000, is a publicly listed company focusing on marketing and sales of internally-developed therapeutic drugs. Haisco ranks third in size in China’s chemical pharmaceutical industry. The company’s products are sold to more than 3,000 hospitals throughout China with annual sales of over US$800 million.

Last year Haisco Group invested in two other Israeli medical device companies: $10 million were invested in October 2015 in Endospan and in July 2015 they invested $5 million in MST – Medical Surgery Technologies.

Sunday, January 10, 2016

Chinese VC to Invest in Pi-Cardia US$10m Round

Pi-Cardia Ltd., the Rehovot, Israel based company, annonced today that it has completed a $10 million financing including participation by a new strategic investor. Also participating in the round, are Italian funds Innogest and Fondo Atlante Ventures, Chinese fund VI-Ventures and existing investors in the company, including Clal Biotechnology Industries and Anatomy Medical Technologies Fund.

Pi-Cardia, founded in 2009, developed the Leaflex™ Catheter System - a novel non-implant based technology for treating patients with aortic valve stenosis. The Leaflex™ is a low-profile trans-femoral catheter incorporating unique Nitinol elements, which are optimized for delivering mechanical energy to create substantial fractures in valve calcification. These fractures help restore leaflet mobility and improve valve hemodynamics using a short and simple procedure without the need to implant a new valve.

The design of the Leaflex™ was based on the company's extensive research in the last few years on calcium growth patterns in hundreds of human aortic valves. Pi-Cardia's Leaflex™ technology and mechanism of action are fundamentally different from those of balloon-based (BAV) devices, in that instead of simply dilating the valve, which might lend itself to the short-term recoil seen in patients treated with BAV, the Leaflex™ creates multiple targeted fractures at optimal locations of valve calcification thereby restoring leaflet mobility. This unique fracturing method, while preserving the native valve integrity, may facilitate valve replacement therapies, as well as pave the way for providing durable treatment without implanting a new valve.

Pi-Cardia aims to expand the treatment options in the rapidly growing multi-billion dollar market currently dominated by surgical or trans-catheter aortic valve replacement (SAVR/TAVR). "As much as TAVR improves and becomes a routine procedure in lower surgical risk patients, it is still a relatively complex and expensive implantation procedure, which restricts its use to specific centers and specific cases" says Erez Golan, Pi-Cardia's Founder and CEO. "In today's budget sensitive environment, waiting lists for TAVR are common even in the most developed countries, let alone in emerging markets, where TAVR may not be a viable option for a while." 

"Besides the typical case of an eighty-five-year-old patient with a tri-leaflet aortic valve, whom I will simply have more options to offer, there are also some common anatomies such as bicuspid aortic valves, where TAVR delivers suboptimal results," says Dr. Ganesh Manoharan, Consultant Cardiologist at the Royal Victoria Hospital, Belfast. "We believe that if a simpler, lower-cost alternative existed, which could offer patients a reasonable period of time without symptoms, such a technique could have an important role alongside TAVR."

In 2015, Pi-Cardia successfully completed enrolling the first set of patients in its FIM study in Europe, demonstrating safety and feasibility of the procedure. The funds raised would allow the company to complete the development of a second generation device, and to continue the clinical studies for showing its safety and performance, towards CE-Mark.

Hengtong GEOC To Invest In Israeli Medical Company Insightec

Israeli medical company InSightec, which has developed a platform for non-invasive therapy for the treatment of early detected cancerous tumors and functional diseases of the nervous system using ultrasound, raised US$22m.

The current investment round is the fourth investment round in the company.

The investors were Boston MedTech Advisors, Elbit Imaging, GE Healthcare, York Capital and Chinese VC fund Hengtong GEOC.

To date, the raised US$254mm, most of the amount of Elbit Medical.

Hengtong GEOC, based in Shanghai, China, is a Sino-Israel fund established in 2013 aiming to invest in Israeli startups and help them to penetrate into Chinese market.

InSightec is the pioneer and global leader in MR guided focused ultrasound technology. Founded in 1999 by GE Healthcare (then GE Medical Systems) and Elbit Medical Imaging its mission is to transform its MR guided Focused Ultrasound (MRgFUS) into a clinically viable technology.

Insightec technology currently found in 120 leading medical centers around the world, can be likened to focusing sunlight through a lens: only the center, where all the waves converge, created enough heat to destroy the tumor, while minimizing damage to adjacent organs damage prevention. Its purpose is to replace surgical procedure Non-invasive treatment that allows the patient to return to his speed.

Tuesday, December 1, 2015

Chinese VC to Invest in Israeli Company IOPtima

Two venture capital funds, one from China and one from Taiwan, are investing $6 million in IOPtima at a company valuation of $20.7 million. Their investment is part of a $7.2 million financing round by the company, in which IOPtima's parent company Bio-Light Israeli Life Sciences Investments Ltd. is also participating with a $1.2 million investment.

The venture capital funds from China and Taiwan will jointly own 29%, and private minority shareholders will own 1%.

IOPtima has developed and begun to market in a number of countries a system for glaucoma operations without penetrating the internal part of the eye.

The proceeds from the financing round will be used mainly for the company's marketing efforts, and $1 million will be used to repay a past loan from Bio-Light.

The investment agreement includes a clause stating that if IOPtima does not generate $13.7 million revenue within three years and/or does not submit a request for marketing approval of one of its products within two years, the investors will be allocated more shares in the company at no additional cost. If the company does not obtain marketing approval in the US within five years, or does not accumulate $13.7 million in revenue within three years, the investors can make a forced sale and offer their holdings to a third party at a value of at least $37 million, subject to first refusal rights for Bio-Light.

"The agreement constitutes confirmation from an external independent source of the quality of IOPtima's technology and business potential," said Bio-Light CEO Suzana Nahum-Zilberberg, "The investment agreement is strategically important for IOPtima and Bio-Light, and is expected to contribute to IOPtima's penetration and sales in global markets, and to the approval process for the product and approval for marketing it in the US and commercializing it in this significant market."

A few months ago, Chinese investor Patrick Lau invested NIS 26 million in Bio-Light for 18.9% of the company. Other shareholders include Israel Makov, the current chairman, and Dilip Shanghvi, founder of Sun Pharmaceuticals, India’s largest pharmaceutical company, who own 12.7% and 14% of the company, respectively.

Thursday, November 19, 2015

ElMindA Raises $28m, Chinese Shanda Group To Participate In The Round

ElMindA Ltd., a pioneer in neuroscience-based technology for analyzing brain network functionality, announced the successful completion of a $28 million Series C financing round.

The global syndicate of investors in this round includes Chinese giant Shanda Group, The Kraft Group, Wexford Capital, WR Hambrecht & Co, Palisade Capital Management, OurCrowd and Healthcrest AG.

Proceeds will be used to continue advancement of ElMindA’s proprietary BNA™ (Brain Network Activation) system, which uses multi-channel EEG-ERP electrophysiology technology to provide a more accurate, objective assessment of brain functionality over time. ElMindA will also use the funds for commercial and clinical adoption following BNA’s 2014 FDA clearance in the U.S., and CE Mark approval in Europe for brain function assessment.

“We are thrilled to have attracted such a strong group of new and existing investors,” said Ronen Gadot, chief executive officer of ElMindA. “This support is a testament to the vast potential of BNA technology to advance our understanding of how the brain works, and to positively impact people’s lives. We plan to bring BNA to the forefront as a significant resource to monitor and manage the health of your brain throughout the course of your life.”

“As an investor who has followed the advancements of the company for several years, we look forward to supporting ElMindA as it further unlocks the potential of BNA to be the preeminent market leader by offering an objective platform for brain function assessment and management of brain disorders,” said Robert Kraft of the Kraft Group.

BNA is a non-invasive technology for measuring and analyzing brain function. It uses advanced signal processing and machine-learning algorithms of big populations’ data in order to identify patterns of neuronal networks activated during a specific brain function, such as memory or attention. The information can then be utilized for personalized clinical decision making. It has the potential to impact an estimated two billion people worldwide living with neurological and psychiatric disorders, such as Alzheimer’s disease, Parkinson’s disease, depression, and ADHD, as well as those who have sustained traumatic brain injuries, like concussion.

“ElMindA has developed a truly disruptive technology that addresses a crucial unmet need,” said Tianqiao Chen of Shanda Group. “We’re excited to help develop and promote such a unique technology that can potentially catalyze new treatment options for those affected by brain dysfunction.”

“BNA’s exploration of brain function has already affected the lives of young people and their physicians in the U.S. seeking additional guidance for critical brain health decisions,” said Bill Hambrecht of WR Hambrecht & Co. “It has the potential to be of value to each and every one of us in our lifetime.”

BNA is currently available to healthcare providers at 15 locations in eight U.S. cities, including Chicago, Los Angeles, Philadelphia, Minneapolis, Phoenix, Ann Arbor, Hartford, and Palm Beach.

Wednesday, October 28, 2015

Fosun Invests $25m In Israeli Medical Company Ornim Medical

Chinese conglomerate Fosun Pharma to invest $25 million in the Israeli company that develops a medical device that uses near infrared light and ultrasound waves to monitor hemoglobin oxygen saturation in the brain and microcirculation blood flow in tissue.

Previews investors in Ornim are OrbiMed and GE Medical.

In 2013 Fosun bought Israeli company Alma Lasers for $240 million.

Wednesday, October 21, 2015

Chinese Group Haisco Pharmaceutical To Invest $10 million in Israeli Company Endospan

Xizang Haisco Pharmaceutical Group Co., China second largest medical corporation invests $ 10 million in Endospan, an Israeli company that develops medical devices.

Post money valuation to the company is $100 million.

Existing shareholders in the company also invested in the round, including Accelmed (Mori Arkin's fund), Dr. Uri Geiger, Sequoia Capital Israel and VitaLife. To date the company raised $25 million, mainly from Accelmed and Sequoia.

Haisco Pharmaceuticals will get exclusive rights for distributing the products of Endospan in China.

Endospan transforms the treatment of aneurysms, dissections and other aortic lesions from high-risk, open- surgery to faster, simpler and less invasive procedures and from conventional, double-sided endovascular procedures, to lower invasiveness, percutaneous, single sided interventions.

Endospan was founded in 2009, based in Herzlyia, Israel and has 30 full-time employees.

Thursday, August 27, 2015

Israel, China medical technology incubators set up shop in Singapore

THE Republic looks set to become a hothouse in Asia for medical technology, as two medtech incubators from Israel and China set up shop here to develop healthcare products for their commercialisation in bigger markets, such as China and the US.

"Now is an opportune time for medtech," said Todd Dollinger and Steve Rhodes, co-chairmen and chief executives of Israel-based Trendlines.

They told BT: "In China, health spending as a share of GDP was 5.6 per cent in 2013, well below the OECD average of 8.9 per cent, while that of the US is 16.4 per cent. Clearly, China must increase spending while the US must bring down costs. Regardless, both countries need quality health products at economically appropriate prices. This presents a tremendous opportunity for medtech."

Founded in 2007, Trendlines invents, discovers, invests in, and incubates medical and agricultural technologies, and is looking to list on Singapore Exchange in November, said Dr Dollinger and Mr Rhodes.

"Even though Singapore has almost no market for agriculture, its tech, research, hospital, logistics and food processing capabilities lend potential for such an incubator here," they said. Slated for launch in Q1 2016, it will hire at least six local staff with strengths in business development, who will first undergo training in Israel.

Currently, Trendlines' Israel-based team of over 30 engineers, scientists and business analysts screen about 500 medtech proposals yearly to identify promising early-stage technologies for incubation. That it partners these new technologies from early days is a "high risk" investment, said Mr Rhodes, but one that is mitigated by the incubator taking an initial large equity position (50-100 per cent) and being extremely involved in the operations of their portfolio companies.

"Even so, we're more flexible than a venture capital fund," said Dr Dollinger. "Venture capitalists are always looking at the clock. At Trendlines, we are not committed to exit our companies at a certain stage or invest at certain times."

Trendlines' portfolio companies - at least six of 60 have exited via a trade sale or public listing - receive up to US$1.1 million in funding, which comprises an Israeli government grant of about US$558,000, a Trendlines' cash investment of about US$98,000 and a follow-up in-kind investment of US$400,000.

Among its investors are many high net worth individuals and corporates from Singapore, said both men. "Singapore and Israel have a long history of R&D and government engagements. Singapore also has a strong interest in Israeli technology and entrepreneurial knowhow, and is both a wonderful ecosystem and a welcoming environment," they added.

Meanwhile, Incubator in China, one of China's newest and largest medtech and pharmaceutical incubators, now has a Singapore presence via homegrown tech incubator Venturecraft. Fresh from launching a S$4 million working capital fund earlier this year, Venturecraft recently partnered and invested in the Chinese incubator, making it a one-stop platform in Singapore for startups looking to commercialise their products or drugs in China.

Venturecraft's services include providing - in China - access to clinical trials, distribution to hospitals and localised marketing strategies; facilitating regulatory approvals and grants from the Chinese government, and even offering rent-free offices at its premises in Hangzhou.

"This is all part of continuing efforts to become a leading bridge in Asia for Singapore and global companies to foray into China," said Isaac Ho, managing partner of Singapore HealthTech, the private investment firm behind Venturecraft.

Mr Ho added that Incubator in China boasts many of China's top medical experts including government and private hospitals chiefs, as well as IP and regulatory experts, reputable distribution partners, R&D laboratories and government agencies.

Moreover, Venturecraft is exploring an initial public offer in "an appropriate market". Said Mr Ho: "Since Venturecraft operates as an evergreen structure, in the future when we have built enough portfolio and assets, we will explore a listing in order to unlock our shareholders' value."

Just last week, Singapore's medtech industry got a fillip from two other announcements. EDBI, the corporate investment arm of the Singapore Economic Development Board, said it has invested in Massachusetts-based life science tools company Rapid Micro Biosystems, while homegrown accelerator JFDI said it has partnered Germany's Medical Innovations Incubator to "power" pioneering medtech startup bootcamps and an accelerator in Germany; both are said to lead to technology transfer and job-creation opportunities here.

Monday, February 16, 2015

Ping An, ZTE and Yongjin to Invest $25mm in Rainbow Medical

Israeli medical innovation investment company Rainbow Medical raised $ 25 million from leading Chinese companies such as Ping An Venture, ZTE Venture Capital (the investment arm of the Chinese mobile phone giant ZTE), Yongjin Group and Highlight Capital. The money raised will be used for the establishment of new companies with strong IP in various stages of clinical and pre-clinical trails in Israel and abroad.

Rainbow was founded in 2008 by entrepreneur Yossi Gross, CEO Efi Cohen-Arazi and GlenRock cooperation (the investment company of the Leon Recanati).

Rainbow's portfolio includes companies like Nano Retina, which develops an artificial retina on a microchip to regain sight to the blind, BlueWind Medical, a developer of a platform for nerve stimulation using a tiny wireless implant for treatment of neuropathic pain and Glusense that develops an implant that can directly measure blood sugar levels in people with diabetes. Overall Rainbow invested in 12 companies that develop products to treat a variety of chronic disease including cardiovascular disease, hypertension and more.

Wednesday, October 29, 2014

China's GoCapital to Invest $12m in Israeli Medical Device Company CNoga

Israel’s CNoga Medical, which develops non-invasive, touch free medical technology, has raised $12.5 million in financing from the Chinese investment fund GoCapital. The investment is the second investment made by GoCapital in Israeli start-up.

The new investment will be used to continue the development of its products.

Former CEO and founder of OPlus Technology, Dr. Yosef Segman, established CNoga Medical in 2004. The company works with international prominent technology companies such as Texas Instruments and PNY Inc., which dominates the US flash memory market.

CNoga Medical is focused on research and development into enhancing and developing its range of non-invasive technologies. The company’s main product is used to check the glucose levels in people who suffer from diabetes.

Its TensorTip Combo Glucometer (CoG) is a non – invasive, needle-free, portable device. CNoga’s patented algorithms and technology transform the current blood glucose test into a painless and easy procedure. CNoga also has a device for monitoring blood pressure. The TensorTip Vital Signs Monitor (VSM) takes advantage of CNoga Medical’s non-invasive technology to offer continuous readings of blood oxygen saturation (SpO2) and pulse rate (PPM) as well as blood pressure (diastolic and systolic), without needles or cuffs.

A detailed panel reveals the capillary pulse waveform and blood pressure variation. Results, past and present, are at your fingertips, stored as easy-to-read history entries in your VSM.

The company previously raised $8 million from private investors in Israel and abroad.

Monday, October 13, 2014

Tencent Leads US$100M Investment in Chinese Medical Service, an online medical service provider, announced today over US$100 million funding which is led by Tencent.

Weiyi, a pair of mobile apps for connecting patients and doctors, will be integrated into Tencent’s mobile messaging apps, WeChat and Mobile QQ, according to the announcement. Guahao means patient appointment scheduling in Chinese. That’s where the company started off in 2010. has introduced more than 900 hospitals in 23 Chinese provincial level regions. Users are able to find all the hospitals and doctors on the site, schedule appointments, read medical tips provided by doctors, or rate hospitals/doctors.

The site has more than 37 million verified users and 120,000 registered doctors, according to the company.

Weiyi is a newly established service that will expand existing offerings to mobile payments, medical record keeping, and more features for interactions between doctors and users. Weiyi will be officially launched later this week.

Medical and healthcare has become another vertical industry, apart from transportation, mobile commerce/payments, and the like, where Chinese Internet giants have begun fighting. Alibaba Group announced a Future Hospital plan earlier this year that would add features similar to what Guahao has and will offer onto Alipay Wallet, the flagship mobile app of the Chinese e-commerce giant.

Before Guahao, Tencent has invested US$70 million in Dingxiangyuan (DXY), a Chinese online medical service which is focused on medical & health information and hospital & doctor data.

Tuesday, October 7, 2014

Two weeks after Xiaomi launches a smart blood pressure monitor, Baiduunveils one of its own

Is this the next frontier in the battle for the internet of things? Chinese web giant Baidu has just announced a smartphone-connected home blood pressure monitor dubbed Mumu BP 2. The Bluetooth-connected device comes just two weeks after smartphone maker Xiaomi released its own sphygmomanometer in partnership with iHealth Labs. Read more: Two weeks after Xiaomi launches a smart blood pressure monitor, Baidu unveils one of its own.

Like Xiaomi and iHealth’s partnership, Mumu and Baidu joined up to create a co-branded device, according to DoNews. Guangzhou-based Mumu also makes an under-the-arm portable blood pressure monitor.

Whereas Xiaomi’s version requires a corded phone dock, Mumu is completely wireless and runs on a rechargeable battery. With the aim of being as simple as possible, it only has two buttons: power and Bluetooth connection. Everything else is controlled by the app. Users can monitor the data in real time and record it on Baidu Cloud, including systolic blood pressure, diastolic blood pressure, and heart rate. To accomodate for older phones – likely those used by elderly users – the device and app are compatible with the older Bluetooth 2.1 and the newer 4.0.

So why are China’s big tech companies suddenly showing an interest in blood pressure? The internet of things and the medical field are quickly converging. As an entry point, sphygmomanometers make sense. They are relatively simple to make, require little expertise to use, and they reach a low common denominator; a World Health Organization report published one year ago shows hypertension affects over 40 percent of Chinese adults aged 45 or older.

The Mumu BP 2 is now available for pre-order in China for US$65 and will ship on November 8.

Xiaomi’s blood pressure monitor is on sale now for just half that price.

Sunday, October 5, 2014

MedAware Raises $1 Million to Bring Big Data Analytics to Medical Prescription Market

RA'ANANA, Israel, October 2, 2014 -- MedAware, a developer of big data analytics for the medical prescription market, announced today that it has completed a $1 million Series A financing round led by equity crowdfunding platform OurCrowd. Together with GE Ventures, it is the two firms' first co-investment since entering into a strategic partnership in November 2013, and GE's first software investment in Israel's growing healthcare industry. The money raised will be used to drive initial sales to healthcare providers, insurance companies and large pharmacy chains.

Today, prescription errors result in morbidity, mortality and wasteful healthcare costs, harming hundreds of thousands of people annually in the United States alone. To combat the prevalence of those errors, MedAware has developed an innovative software-based solution that combines the power of big data analytics and machine learning to save lives and reduce medical costs.

"Three years ago I came across a tragic case of a nine-year-old Israeli boy who died because his primary-care physician accidentally prescribed the wrong drug," said MedAware Co-founder and CEO Gidi Stein. "The ease with which a little boy died because of a mistaken click of a button was horrifying to me as a physician and as a parent. We have founded MedAware in order to try and prevent such cases."

Current solutions such as electronic medical records and computerized physician order entry systems search for prescription errors based on manually predefined rules. These systems miss errors that do not fall into their known rules, and also suffer from high false-alarm rates. By contrast, MedAware uses big-data analytics and machine-learning algorithms to automatically learn how different clinical scenarios are managed by physicians in real world situations.

"MedAware embodies many of the same technologies we've seen accompany the emergence of the Industrial Internet," added Jason Sibley, Director of Healthcare Ventures at GE Ventures. "From big data and analytics to machine learning and digital communications, the company aligns perfectly with GE's vision for a healthcare industry driven by technology and built for improving lives, and we look forward to working together to help transform the medical prescription market."

"We are excited about the potential for MedAware to solve the huge problem of prescription error via their impressive big data technology," said Jon Medved, founder and CEO of OurCrowd. "The fact that our partner, General Electric, has joined together with us in this investment is further validation of this tremendous opportunity."

Saturday, September 20, 2014

Xiaomi To Invest 25 million in Medical Device iHealth Lab

Chinese smartphone maker Xiaomi Inc.'s venture capital arm has agreed to invest US$25 million in Chinese health products maker Andon Health Company Limited, according to a regulatory filing.

Tianjin-based Andon Health will establish a new entity called iHealth Inc. in Cayman Island, and inject its related global businesses in electronic and smart health device division iHealth into the new platform.

Xiaomi Ventures Limited will hold a 20% stake of iHealth Inc.

The two will develop new health products and services that can be applied to Xiaomi's e-commerce and cloud platforms.

The investment is part of Xiaomi's drive to invest in emerging new technologies, and to expand service offerings in healthcare, payment, e-commerce and more on its smartphone devices. For example, earlier in September, Xiaomi teamed up with Shunwei Capital Partners, a venture fund established by Xiaomi's founder Lei Jun, to lead a US$37.19 million series B financing in P2P (Peer-to-Peer) lending platform 

Established in 1995, Andon is one of the largest makers of blood pressure monitors and blood glucose meters globally.

In August 2013 Xiaomi led an investment round in Israeli gesture control company Pebbles Interfaces.

Sunday, September 14, 2014

Israel's Insightec to receive $12.5 Million investment from Chinese Investors

Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) announced today that it was informed by InSightec Ltd. of the closing of investment of US$ 12.5 million by Shanghai GEOC Hengtong Investment Limited Partnership and Fortune China Limited.In the framework of the present investment round in InSightec, the Chinese Group has acquired 5% of the share capital of InSightec on a fully diluted basis, in consideration for a total payment of $12.5 million.

InSightec is the pioneer and global leader in MR guided focused ultrasound technology. Founded in 1999 by GE Healthcare (then GE Medical Systems) and Elbit Medical Imaging its mission is to transform its MR guided Focused Ultrasound (MRgFUS) into a clinically viable technology.

Since then, InSightec has invested close to $200 million in research and development. The company holds over 90 patents with additional intellectual property pending.

The company is headquartered in Tirat Carmel, Israel, near the port city of Haifa. It has US offices in Milwaukee, WI and Dallas, TX as well as offices in Europe and Asia.

Thursday, September 11, 2014

Israeli medical device company Inovytec signed a strategic agreement with Chinese comapny Haier

Israeli medical device company Inovytec Medical Solutions Ltd. announce a strategic agreement with Chinese company Haier. Inovytec specializes in providing advanced, state-of-the-art, non-invasive critical care devices for Pre-hospital and Out of Hospital use, by professional and non-professional caregivers under emergency conditions.

Inovytec products are molded to address the 21st Century emergency care expectations, where reliable, fail-safe, and simple to use emergency care will be immediately available for use on-site with the highest assurance of success. Inovytec devices are designed to save lives where the first few minutes are crucial. Not only in cases of SCA (Sudden Cardiac Arrest), but also in a variety of respiratory, cardiac, central nervous system and trauma emergencies in which airway management, oxygen therapy , monitoring and defibrillating may be required. Inovytec devices are designed to be operated by local caregivers under all conditions that require immediate intervention and assistance. This includes public areas, ambulatory, EMS (Emergency Medical Services), and others.

The critical care market in China has a potential of $500 million per year and is expected to grow up to $10 billion. Inovytec devices will be deployed in more than 900,000 local clinics and later will also enter the domestic market.

BATM to Invest in Israeli Medical Device Startup Opticul Diagnostics

BATM Advanced Communications Ltd. to invest up to $450,000 in the Israeli in vitro diagnostics medical device company, Opticul Diagnostics.

BATM provides real-time technologies for the networked telecoms and medical laboratory equipment markets. Opticul has developed a process for rapid diagnosis, using photonic laser technologies, of micro-organisms based on their outer morphology. The process - applied through the Optidet device - enables faster, lower cost and more reliable diagnostics compared with current technologies.

Opticul and BATM will conduct joint R&D in the U.S. and Israel to develop and launch the next prototype of Optidet. Of the agreed investment, $200,000 is being paid upfront in cash and the remainder as milestones are achieved. BATM will own 20% of the issued share capital of Opticul Diagnostics.

Opticul has already obtained US Food and Drug Administration (FDA) and European ISO approval for an early prototype. BATM CEO Dr. Zvi Marom said, "Opticul has invented a truly disruptive technology that is able to identify a type of bacteria in minutes instead of days. This investment is complementary to our diagnostics business and adds another technology offering to our portfolio."

Source: Globes

Friday, September 5, 2014

Fosun Pharma to Invest $46.2 million in Nature's Sunshine

Nature's Sunshine Products, Inc., a leading natural health and wellness company engaged in the manufacture and direct selling of nutritional and personal care products, announced the closing of its China joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and private placement transaction of 2.854 million shares of common stock, representing approximately 15% of Nature's Sunshine's outstanding common shares, to Fosun Pharma at a price of $16.19 per share. Aggregate proceeds to Nature's Sunshine were approximately $46.2 million.

The joint venture, known as Nature's Sunshine Hong Kong Limited, is 80% owned by Nature's Sunshine and 20% owned by a wholly-owned subsidiary of Fosun Pharma.

Shanghai Fosun Pharmaceutical is a leading listed company in China's pharmaceutical industry and was listed on Shanghai Stock Exchange in August 1998 and on the Main Board of the Stock Exchange of Hong Kong Limited in October 2012. Its main business includes pharmaceutical manufacturing, distribution and retail; healthcare services; diagnostic products and medical device. 

In May 2013 Fosun Pharma bought Israeli company Alma Lasers for $240 million.